Merck & Co. (MRK) fundamentals: P/E, valuation, undervalued?
Merck & Co. · Health Care · ref. ETF XLV · price $141.98
In short — Merck & Co. trades at 112.7× earnings (P/E), 15.2× forward, with a net margin of 4.8 % and revenue growth of +5 %. Read: Very high P/E (P/E 113 (well above average)).
Is Merck & Co. stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$141.98+67.6% over range
Oct 14, 25low $82.49 · high $156.45Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
84% recommend buying · 19 analysts
Valuation : Very high P/E — P/E 113 (well above average)
Valuation
112.7
P/E (price/earnings)
15.2
Forward P/E
—
PEG
8.4
Price/book (P/B)
$350.3B
Market cap
1.26
EPS
Profitability & growth
4.8 %
Net margin
+5 %
Revenue growth
—
Earnings growth
$53.9B
Total debt
Merck & Co. income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2022 | $59.3B | $14.5B | 24.5 % |
| 2023 | $60.1B | $365M | 0.6 % |
| 2024 | $64.2B | $17.1B | 26.7 % |
| 2025 | $65.0B | $18.3B | 28.1 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Merck & Co.'s P/E and is the stock undervalued? What's a good P/E?
Merck & Co.'s P/E is 112.7 (forward 15.2). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Very high P/E".
Is Merck & Co. profitable?
Merck & Co. has a net margin of 4.8 % (EPS 1.26). The company is profitable.
Is MRK stock expensive?
Our read: "Very high P/E" — P/E 113 (well above average). Cross-check with growth and sector.
💬 A question about Merck & Co.? The JPI assistant answers using our backtest data.